A more nuanced management approach to SRMs is therefore needed to try and maximise oncological control whilst minimising over-treatment. This treatment paradigm continues to evolve with evidence now supporting the efficacy and safety of active surveillance, lesion biopsy, and ablative therapies in well selected patients. In addition, surgical excision in the form of partial nephrectomy (PN) has demonstrated excellent oncological control with maximal renal preservation. Previously limited by procedural and technical factors in the open and laparoscopic era, the proliferation of robotic-assisted surgery has seen an increase in the utilisation of PN for SRMs. There are now over 80 robotic surgeons performing over 1000 procedures across the UK.